SRR1399028
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.398
- SPERMATOGENESIS+0.322
- PANCREAS_BETA_CELLS+0.274
- HEDGEHOG_SIGNALING+0.228
- MYOGENESIS+0.210
- OXIDATIVE_PHOSPHORYLATION+0.170
- APICAL_JUNCTION+0.167
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.149
- ESTROGEN_RESPONSE_LATE+0.064
- ESTROGEN_RESPONSE_EARLY+0.034
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.525
- IL6_JAK_STAT3_SIGNALING-0.508
- INTERFERON_GAMMA_RESPONSE-0.505
- E2F_TARGETS-0.461
- TGF_BETA_SIGNALING-0.452
- PROTEIN_SECRETION-0.430
- MYC_TARGETS_V1-0.427
- G2M_CHECKPOINT-0.423
- INFLAMMATORY_RESPONSE-0.392
- TNFA_SIGNALING_VIA_NFKB-0.381
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1466993 | GTEX | — | 0.981 |
| 2 | SRR1357523 | GTEX | — | 0.973 |
| 3 | SRR1343841 | GTEX | — | 0.970 |
| 4 | SRR1490019 | GTEX | — | 0.970 |
| 5 | SRR1464451 | GTEX | — | 0.969 |
| 6 | SRR1324371 | GTEX | — | 0.969 |
| 7 | SRR1353176 | GTEX | — | 0.968 |
| 8 | SRR1323746 | GTEX | — | 0.968 |
| 9 | SRR1320280 | GTEX | — | 0.967 |
| 10 | SRR1459441 | GTEX | — | 0.967 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.398 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.322 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.274 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.228 | Inavolisib | — uncovered |
| MYOGENESIS | 0.210 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.170 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.167 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.149 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.064 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.034 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.014 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.008 | Inavolisib | — uncovered |